Advertisement

Topics

Novo Nordisk’s New Type 2 Diabetes Drug Outperforms Eli Lilly’s

07:24 EDT 18 Aug 2017 | Labiotech.eu

Novo Nordisk has reported Phase III data that reveal its candidate semaglutide improved glucose control and weight loss in type 2 diabetes when compared with Eli Lilly’s dulaglutide. The results of the SUSTAIN 7 trial comparing the efficacy of Novo ...

This awesome article Novo Nordisk’s New Type 2 Diabetes Drug Outperforms Eli Lilly’s appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: Novo Nordisk’s New Type 2 Diabetes Drug Outperforms Eli Lilly’s

NEXT ARTICLE

More From BioPortfolio on "Novo Nordisk’s New Type 2 Diabetes Drug Outperforms Eli Lilly’s"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...